Algeta Expands its TH-1 Targeted Cancer Therapy Program
Research collaboration established for the discovery of radioimmunotherapeutic approaches to cancer treatment
Algeta ASA announced the continued expansion of its novel TH-1 research program to develop effective, antibody-based approaches to the treatment of cancer. Under the terms of a newly established collaboration, Algeta has initiated a feasibility study agreement with an undisclosed partner specialised in antibody-based therapeutics. The collaboration is aimed at linking the alpha emitter Thorium-227 to tumor-selective antibodies developed by the partner. Pursuing a jointly developed and managed research collaboration, both parties will upon completion assess the development and commercialization potential of Thorium-227-based immunotherapeutic products.
This expansion of the TH-1 targeted cancer therapy program at Algeta complements an ongoing research collaboration with Affibody initiated in August 2006, aimed at exploring the potential of the TH-1 technology in the context of Affibody's novel cancer-targeting molecules. Initial data have been gathered together with Affibody and the research under this contract continues.
Furthermore, Algeta recently announced the extension of its TH-1 collaboration with The Norwegian Radium Hospital, for the evaluation and development of tumor-selective therapeutics based on alpha-emitters.
Other news from the department business & finance
